1. Home
  2. OPHC vs ENGN Comparison

OPHC vs ENGN Comparison

Compare OPHC & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OptimumBank Holdings Inc.

OPHC

OptimumBank Holdings Inc.

N/A

Current Price

$9.11

Market Cap

110.1M

Sector

Finance

ML Signal

N/A

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

N/A

Current Price

$1.46

Market Cap

117.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
OPHC
ENGN
Founded
2000
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
110.1M
117.2M
IPO Year
2012
2023

Fundamental Metrics

Financial Performance
Metric
OPHC
ENGN
Price
$9.11
$1.46
Analyst Decision
Strong Buy
Buy
Analyst Count
3
9
Target Price
★ $10.92
$3.29
AVG Volume (30 Days)
57.3K
★ 822.7K
Earning Date
11-13-2026
12-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 56.85
EPS
★ 0.48
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.08
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.92
$1.40
52 Week High
$10.68
$12.25

Technical Indicators

Market Signals
Indicator
OPHC
ENGN
Relative Strength Index (RSI) 54.60 33.12
Support Level $8.48 $1.40
Resistance Level $9.26 $1.95
Average True Range (ATR) 0.38 0.09
MACD 0.04 -0.01
Stochastic Oscillator 67.16 3.35

Price Performance

Historical Comparison
OPHC
ENGN

About OPHC OptimumBank Holdings Inc.

OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: